London, 1 September, 2021 – OKYO Pharma Limited (LSE: OKYO) (“OKYO” or the “Company”), the life sciences and biotechnology company, focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and chronic pain, is pleased to announce, announces that the board of directors of the Company (the “Board” or “Directors“), with Mr Brancaccio absenting himself on grounds of interest, has awarded the following options on 31 August 2021.
(a) Gary Jacob
Mr Jacob has been awarded options to acquire 13,000,000 ordinary shares in the capital of the Company. The options are exercisable at a price of 4.9 pence per share (being the mid-market closing price of the Company’s shares traded on the LSE on 31 August 2021). The options will vest in equal tranches over four years beginning on the date of grant.
Keeren Shah
Ms Shah has been awarded options to acquire 500,000 ordinary shares in the capital of the Company. The options are exercisable at a price of 4.9 pence per share (being the mid-market closing price of the Company’s shares traded on the LSE on 31 August 2021). The options will vest in equal tranches over four years beginning on the date of grant.
(b) John Brancaccio
Mr Brancaccio has been awarded options to acquire 900,000 ordinary shares in the capital of the Company. The options are exercisable at a price of 4.9 pence per share (being the mid-market closing price of the Company’s shares traded on the LSE on 31 August 2021). The options will vest in equal tranches over four years beginning on the date of grant.
This information set out below is provided in accordance with Article 19(3) of EU Regulation 596/2014.
| 1. | Details of PDMR / person closely associated | |||||||
| a) | Name | (i) Gary Jacob (ii) Keeren Shah (iii) John Brancaccio | ||||||
| 2. | Reason for the notification | |||||||
| a) | Position / status | (i) Chief Executive Officer (ii) Chief Financial Officer (iIi) Non-Executive Director | ||||||
| b) | Initial notification /amendment | Initial notification | ||||||
| 3. | Details of the issuer | |||||||
| a) | Name | OKYO Pharma Limited | ||||||
| b) | LEI | 213800VVN5CB56Y15A05 | ||||||
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||||
| a) | Description of the financial instrument | Ordinary Shares of no par value | ||||||
| b) | Identification code of the Financial Instrument | ISIN for OKYO Pharma Limited: GG00BD3FV870 | ||||||
| c) | Nature of the transaction | Grant of options | ||||||
| d) | Price(s) and volume(s) |
(iii) 4.9p (iii) 900,000 | ||||||
| f) | Date of the transaction | 31 August 2021 | ||||||
| g) | Place of the transaction | XLON | ||||||
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.
OKYO Pharma Limited (LSE: OKYO) is a life sciences and biotechnology company admitted to listing on the standard segment of the Official List of the UK Financial Conduct Authority and to trading on the Main Market for listed securities of the London Stock Exchange plc. OKYO is focusing on the discovery and development of novel molecules to treat inflammatory dry eye diseases and chronic pain.
Enquiries:
| OKYO Pharma Limited | Willy Simon | +44 (0)20 7495 2379 |
| Optiva Securities Limited | Robert Emmet | + 44 (0)20 3981 4173 |
For further information, please visit the Company’s website at www.okyopharma.com.